Division of Critical Care Neurology, Mayo Clinic, 200 First Street, Rochester, MN 55905, USA.
Published: February 2009
AI Article Synopsis
Article Abstract
Intracerebral hemorrhage (ICH) is a common and devastating condition. Its incidence is expected to increase as the population ages, and its epidemiology is changing. Advances in understanding the pathogenesis of ICH have recently been made. A number of recently completed and ongoing trials suggest that new treatments that limit the mortality and morbidity of ICH may be on the horizon.
Background: Delayed cerebral ischemia (DCI) occurs in approximately 20%-30 % of patients with subarachnoid hemorrhage (SAH). This is the most common complication of SAH and has a high mortality rate. In the present study, we investigated the relationship between hemoglobin (Hb) values and DCI and aimed to determine a cutoff Hb value to be used as a predictor of DCI.
Intrathecal nicardipine (ITN) is an investigational therapy for cerebral vasospasm (CVS) and delayed cerebral ischemia (DCI) in patients with aneurysmal subarachnoid hemorrhage (aSAH). The objective of this scoping review was to characterize the current state of the literature and map the current available evidence, examine research methodology, clarify key concepts and definitions in the literature, report procedural characteristics, identify and analyze knowledge gaps, and serve as a precursor for future systematic reviews, meta-analyses, and randomized controlled trials. An electronic search for studies on ITN for the treatment of CVS and DCI in patients with aSAH was conducted in accordance with published standards.
Purpose: Familial cerebral cavernous malformation syndrome (FCCM) is characterized by multiple hemorrhagic lesions and is sometimes mistaken for cerebral amyloid angiopathy (CAA).
Methods: We compared clinical and radiologic characteristics in patients with definite (N = 32) and presumed FCCM (n = 76) to patients with definite (N = 29) and probable CAA (N = 21).
Intracerebral hemorrhage (ICH) is a severe stroke subtype with high mortality and limited therapeutic options. The blood-brain barrier (BBB) breakdown post-ICH exacerbates secondary brain injury, highlighting the need for targeted therapies to preserve the BBB integrity. We aim to investigate the role of the Sphk1/S1P pathway in BBB breakdown following ICH and to evaluate the therapeutic potential of Sphk1 inhibition in mitigating this breakdown.
